Molecular Matrix, Inc. (MMI) was incorporated on August 2011 as a preclinical state biotechnology company.
MMI is dedicated to developing an innovative new generation platform tissue regeneration technology for musculoskeletal applications, specifically bone.
Our first product is a non-mineralized bone graft substitute to be used in a multitude of different applications and treatments, most commonly in orthopedic surgery for filling defects. MMI’s scaffold technology eliminates the inherent disadvantages associated with current bone graft substitute, including disease transmission, insufficient bone formation, inadequate absorption, interference with evaluation of bone formations, and inability to carry biologics or small molecules. We will provide this product in granular, strip, putty, and custom formulation for general orthopedic applications.